Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
2 Dividend Stocks to Buy Hand Over Fist in November
10:15am, Thursday, 14'th Nov 2024
These companies have solid businesses and excellent dividend growth track records.
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
08:15am, Thursday, 14'th Nov 2024
AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migr
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
05:31am, Thursday, 14'th Nov 2024
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Al
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
01:52pm, Tuesday, 12'th Nov 2024
On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials.
AbbVie's loss is Bristol Myers Squibb's gain - analyst
11:36am, Tuesday, 12'th Nov 2024
Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed.
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains
10:31am, Tuesday, 12'th Nov 2024
ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises.
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
08:53am, Tuesday, 12'th Nov 2024
AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda.
Buy, Sell, Or Hold AbbVie Stock?
07:14am, Tuesday, 12'th Nov 2024
AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primar
Final Trades: Lyft, Meta, United States Oil Fund & Abbvie
07:23pm, Monday, 11'th Nov 2024
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
AbbVie And Pfizer: Q3 Dividend Checkup Post-Earnings
06:45pm, Monday, 11'th Nov 2024
I review both AbbVie and Pfizer's recent earnings reports via the window of dividends following Peter Lynch's wisdom. Lynch's insights into dividend stocks are often in the shadow of his reputation as
Is AbbVie Still A Strong Buy After Fantastic Gains? (Rating Downgrade)
05:00pm, Monday, 11'th Nov 2024
AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. There are three significant reasons for optimism from here. However, the dividend yield is ne
AbbVie Stock: Keep Calm And Buy The Dip
03:50pm, Monday, 11'th Nov 2024
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market reaction appears excessive and presents a buying opportunity. Dividend yield and robus
Why AbbVie Stock Was Getting Mashed on Monday
03:22pm, Monday, 11'th Nov 2024
A splashy recent acquisition by the company might not be panning out.
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
01:32pm, Monday, 11'th Nov 2024
AbbVie Inc (NYSE: ABBV) saw its stock fall nearly 13% after reporting disappointing mid-stage trial results for emraclidine, an experimental treatment for schizophrenia. This setback is notable as Abb
Trade Tracker: Jim Lebenthal buys more Abbvie
01:06pm, Monday, 11'th Nov 2024
Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to discuss why he's buying more of the pharma stock on this dip.
